Trial Condition(s):

Prophylaxis, Thromboembolism, Venous, Total Knee Replacement, Total Hip Replacement

Study to observe safety of Xarelto in VTE prophlylaxis after elective TKR (Total Knee Replacement) or THR (Total Hip Replacement) (XYRIS)

Bayer Identifier:

15871

ClinicalTrials.gov Identifier:

NCT01523418

EudraCT Number:

Not Available

Terminated/Withdrawn

Trial Purpose

The primary objective of this study is to evaluate the safety of Xarelto in the prophylaxis of VTE in Indian patients undergoing elective TKR/THR

Inclusion Criteria
-  Adult patients of either sex, undergoing elective THR/TKR, in whom, Rivaroxaban is given for thromboprophylaxis
 - Patients willing to give a written informed consent
Exclusion Criteria
- Exclusion criteria must be read in conjunction with the local product information
 - Patients on UFH / LMWH therapy, fondaparinux and vitamin K antagonists are not eligible.
 - Patients with history of hypersensitivity to active ingredients or excipient :cellulose microcrystalline, croscarmellose sodium, lactose monohydrate, magnesium stearate, sodium lauryl sulfate

Trial Summary

Enrollment Goal
0
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Locations
Status
LocationsStatus

Trial Design